Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely used for treating type 2 diabetes mellitus (T2DM) as they lower blood glucose more potently than conventional oral drugs and reduce body weight (BW) with less risk of hypoglycemia [1,2,3,4]. This evidence concerns the gene GLP1R and diabetes mellitus.